103 results
6-K
EX-99.1
GMAB
Genmab
14 Feb 24
Genmab 2023 Annual Report
12:30pm
Relapsed/refractory chronic lymphocytic leukemia (CLL) & Richter’s Syndrome Indolent NHL pediatric patients Tisotumab vedotin Co-development Genmab/Seagen
6-K
EX-99.1
GMAB
Genmab
25 Sep 23
Current report (foreign)
8:53am
therapeutic target in many B-cell malignancies, including DLBCL, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.vi,vii … .
vi Rafiq, Butchar, Cheney, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells
6-K
EX-99.1
GMAB
Genmab
21 Jul 23
Current report (foreign)
9:08am
validated therapeutic target in many B-cell malignancies, including DLBCL, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.vi,vii … of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
6-K
EX-99.1
GMAB
Genmab
10 Aug 22
Genmab Announces Financial Results for the First Half of 2022
11:25am
-cell non-Hodgkin lymphoma (B-NHL) including chronic lymphocytic leukemia (NCT04623541) and in combination with standard of care therapies for B-NHL
6-K
EX-99.1
mta8drol7uq41ydy
18 Jul 22
Current report (foreign)
11:08am
6-K
EX-99.1
7v9x9ro ll2ct
30 Jun 22
Current report (foreign)
2:32pm
6-K
EX-99.1
nvyh4ciy6m9mw
11 May 22
Genmab Announces Financial Results for the First Quarter of 2022
11:24am
6-K
EX-99.1
587ctgjwtx
13 Apr 22
Current report (foreign)
5:28pm
6-K
EX-99.1
y48qz
16 Feb 22
Genmab 2021 Annual Report
11:29am
6-K
EX-99.1
y9cfpfah z6s0s9y6vmo
16 Feb 22
Genmab 2021 Annual Report
11:29am
6-K
EX-99.1
eyfm3f
10 Nov 21
Genmab Announces Financial Results for the First Nine Months of 2021
12:01pm
6-K
EX-99.1
odqoukfe
11 Aug 21
Genmab Announces Financial Results for the First Half of 2021
11:46am
6-K
EX-99.1
0ba4ga izm
5 May 21
Genmab Announces Financial Results for the First Quarter of 2021
12:54pm
6-K
EX-99.1
oq3674341p3enxa
30 Mar 21
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
9:54am
6-K
EX-99.1
yx7hc6 sccuszgt3jq
23 Feb 21
Genmab 2020 Annual Report
12:38pm
6-K
EX-99.1
rrp5d
23 Feb 21
Genmab 2020 Annual Report
12:38pm
6-K
EX-99.1
o7973pparsa1kjcv8kg
29 Jan 21
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
2:39pm